Berberine for Appetite Suppressant and Prevention of Obesity
- PMID: 33415147
- PMCID: PMC7752296
- DOI: 10.1155/2020/3891806
Berberine for Appetite Suppressant and Prevention of Obesity
Abstract
Berberine (BBR), a natural plant product, has been shown to have antidiabetic, cholesterol-reducing effects. To investigate the action of BBR as appetite suppressants, two experimental protocols were performed. In the first experiment, the mice were fed either a normal-chow diet or a high-fat diet (HF). The mice received daily intraperitoneal injections of BBR (10 mg/kg or saline at 1 ml/kg) for 3 weeks. To determine the antiobesity effects of BBR, the food consumption, body weight, fat contents, serum leptin, and glucose level were investigated. In the second experiment, we set out to validate the effect of BBR on central neuropeptide Y (NPY) stimulated rats. Experiments were carried out in 24-hour fasted rats, and then food intake and glucose level were subsequently recorded for 1 hour. The experimental groups were subdivided into the intra-3rd ventricular microinjections of ACSF (artificial cerebrospinal fluid), neuropeptide Y (NPY; 100 nM), NPY+BBR (10 nM), and NPY+BBR (100 nM) group. And then the blood glucose level was examined. In the first experiment, treatment with BBR in the HF diet mice reduced food intake, body weight, fat contents, serum leptin, and glucose level. In the second experiment, the NPY-injected group increased food intake by 39.3%, and food intake was reduced in the BBR group by 47.5%, compared with the ACSF-injected group. Also, the serum glucose level in the NPY+BBR (100 nM) group was significantly lower than that in the NPY (100 nM) group. The results suggest that BBR improved lipid dysregulation in obesity by controlling the central obesity related pathway.
Copyright © 2020 Hyun-Jung Park and EunYee Jung.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.Mol Pharmacol. 2017 Feb;91(2):110-122. doi: 10.1124/mol.116.106617. Epub 2016 Dec 8. Mol Pharmacol. 2017. PMID: 27932556 Free PMC article.
-
Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity.Am J Physiol Endocrinol Metab. 2009 Apr;296(4):E812-9. doi: 10.1152/ajpendo.90710.2008. Epub 2009 Jan 27. Am J Physiol Endocrinol Metab. 2009. PMID: 19176354
-
Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats.Metabolism. 2011 Feb;60(2):298-305. doi: 10.1016/j.metabol.2010.02.005. Epub 2010 Mar 20. Metabolism. 2011. PMID: 20304443
-
Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice.Diabetes. 1996 Apr;45(4):531-5. doi: 10.2337/diab.45.4.531. Diabetes. 1996. PMID: 8603777
-
Pharmacology of appetite suppression.Prog Drug Res. 2000;54:25-58. doi: 10.1007/978-3-0348-8391-7_2. Prog Drug Res. 2000. PMID: 10857385 Review.
Cited by
-
Berberine Reduces Lipid Accumulation in Obesity via Mediating Transcriptional Function of PPARδ.Int J Mol Sci. 2023 Jul 18;24(14):11600. doi: 10.3390/ijms241411600. Int J Mol Sci. 2023. PMID: 37511356 Free PMC article.
-
Antifungal alkaloids from Mahonia fortunei against pathogens of postharvest fruit.Nat Prod Bioprospect. 2023 Apr 4;13(1):10. doi: 10.1007/s13659-023-00374-3. Nat Prod Bioprospect. 2023. PMID: 37012512 Free PMC article.
-
Advances of berberine against metabolic syndrome-associated kidney disease: Regarding effect and mechanism.Front Pharmacol. 2023 Feb 6;14:1112088. doi: 10.3389/fphar.2023.1112088. eCollection 2023. Front Pharmacol. 2023. PMID: 36814494 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
